Aria F. Olumi, MD, is a urologist at the Massachusetts General Hospital Department of Urology. He specializes in the treatment of cancer and related research.
ResearchDr. Olumi's laboratroy focuses on mechanisms of inducing death in cancer cells. The laboratory has been investigating the drug, TRAIL, that induces death in cancer cells, but not normal cells, therefore, patients experience minimal side effects from the drug. Since some cancer cells develop resistance to the drug, TRAIL, the laboratory is investigating molecular mechanisms to convert resistant cancer cells to become sensitive. The Olumi lab has identified two novel pathways of regulating resistant cancer cells (c-Fos and FBXL10). The research can lead to improvement of currently available cancer therapies and development of new cancer therapy agents.
Zhang X, Zhang L, Yang H, Huang, X, Otu H, Liberman T, DeWolf WC, Khosravi-Far R, Olumi AF. c-Fos as a pro-apoptotic agent in TRAIL-induced apoptosis in prostate cancer cells. Cancer Research, 2007, 67: 9425-34.
Li W, Wu CH, Febbo PG, Olumi AF. Stromally expressed c-Jun regulates proliferation of prostate epithelial cells. American Journal of Pathology, 2007, Oct;171:1189-98.
Zhang X*, Huang X*, Olumi AF (*contributed equally). Repression of NF-kB and Activation of AP-1 Enhance Apoptosis in Prostate Cancer Cells. International Journal of Cancer. 2009;124(8):1980-9.
Olumi AF, DeWolf WC. The Hybrid of Basic Science and Clinical Training for the Urologic Oncologist: Necessity or Waste? Urologic Oncology. 2009;27:205-7.
September is Prostate Health Month. MGH urologists discuss the prostate, its impact on men’s health and offer advice on PSA screenings.